We draw on long experience in glyco-biology to adress tumor specific glyco-epitope targets with potential for powerful anti-cancer activity. Get in touch!
Investors 1
| Date | Name | Website |
| - | Eckert Lif... | elsalifesc... |
Mentions in press and media 2
| Date | Title | Description |
| 30.04.2021 | Glycotope Announces Poster Presentations at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting | Glycotope Announces Poster Presentations at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting Berlin, Germany, April 30, 2021 - Glycotope GmbH, a biotechnology company developing antibodies against proteins carryi... |
| 13.02.2021 | Another Keytruda combo tops standard of care in advanced kidney cancer, posing new test for Bristol's I/O med | Two months after one of the largest single private funding rounds for a biotech company in European history, German cancer drug developer BioNTech is gunning for a $100 million US IPO. Helmut Jeggle Keep reading Endpoints with a free subscr... |